Publications by authors named "Michael Method"

Claim this Profile
H
Heterogeneity and Scoring Reproducibility of Folate Receptor 1 Immunohistochemistry in High-grade Serous Carcinoma.
Brooke Liang, Troy B Tenney, Lucy Han, Xiaoming Zhang, Aihui Wang, Michael Method

Int J Gynecol Pathol· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with pembrolizumab in patients with platinum-resistant ovarian cancer.
Ursula A Matulonis, Ignace Vergote, Kathleen N Moore, Lainie P Martin, Cesar M Castro, Michael Method

Gynecol Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selinexor plus ruxolitinib in JAK inhibitor treatment-naïve myelofibrosis: SENTRY Phase 3 study design.
John Mascarenhas, Keri Maher, Raajit Rampal, Prithviraj Bose, Nikolai Podoltsev, Michael Method

Future Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exposure-response relationships of mirvetuximab soravtansine in patients with folate receptor-α-positive ovarian cancer: Justification of therapeutic dose regimen.
Ya-Ping Tu, H Maxime Lagraauw, Michael Method, Yuemei Wang, Eva Hanze

Br J Clin Pharmacol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and tolerability of mirvetuximab soravtansine monotherapy for folate receptor alpha-expressing recurrent ovarian cancer: An integrated safety summary.
Kathleen N Moore, Domenica Lorusso, Ana Oaknin, Amit Oza, Nicoletta Colombo, Michael Method

Gynecol Oncol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mirvetuximab soravtansine in folate receptor alpha (FRα)-high platinum-resistant ovarian cancer: final overall survival and post hoc sequence of therapy subgroup results from the SORAYA trial.
Robert L Coleman, Domenica Lorusso, Ana Oaknin, Sabrina Chiara Cecere, Hannelore Denys, Michael Method

Int J Gynecol Cancer· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer.
Debra L Richardson, Kathleen N Moore, Ignace Vergote, Lucy Gilbert, Lainie P Martin, Michael Method

Gynecol Oncol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetics of mirvetuximab soravtansine in patients with folate receptor-α positive ovarian cancer: The antibody-drug conjugate, payload and metabolite.
Ya-Ping Tu, Eva Hanze, Fengying Zhu, H Maxime Lagraauw, Callum M Sloss, Michael Method

Br J Clin Pharmacol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer.
Kathleen N Moore, Antoine Angelergues, Gottfried E Konecny, Yolanda García, Susana Banerjee, Michael Method

N Engl J Med· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply to Z.R. McCaw et al.
Ursula A Matulonis, Domenica Lorusso, Ana Oaknin, Sandro Pignata, Andrew Dean, Michael Method

J Clin Oncol· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study.
Ursula A Matulonis, Domenica Lorusso, Ana Oaknin, Sandro Pignata, Andrew Dean, Michael Method

J Clin Oncol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.
Lucy Gilbert, Ana Oaknin, Ursula A Matulonis, Gina M Mantia-Smaldone, Peter C Lim, Michael Method

Gynecol Oncol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A real-world US study of recurrence risks using combined clinicopathological features in HR-positive, HER2-negative early breast cancer.
Kristin M Sheffield, Jessica R Peachey, Michael Method, Brenda R Grimes, Jacqueline Brown

Future Oncol· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A real-world retrospective study of the use of Ki-67 testing and treatment patterns in patients with HR+, HER2- early breast cancer in the United States.
Jacqueline Brown, Savannah Scardo, Michael Method, Dan Schlauch, Amanda Misch

BMC Cancer· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Standardized Investigational Ki-67 Immunohistochemistry Assay Used to Assess High-Risk Early Breast Cancer Patients in the monarchE Phase 3 Clinical Study Identifies a Population With Greater Risk of Disease Recurrence When Treated With Endocrine Therapy Alone.
Monika D Polewski, Gitte B Nielsen, Ying Gu, Aaron T Weaver, Gavin Gegg, Michael Method

Appl Immunohistochem Mol Morphol· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Breast cancer-specific mortality in early breast cancer as defined by high-risk clinical and pathologic characteristics.
David R Nelson, Jacqueline Brown, Aki Morikawa, Michael Method

PLoS One· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of Slide Storage on Detection of Molecular Markers by IHC and FISH in Endometrial Cancer Tissues From a Clinical Trial: An NRG Oncology/GOG Pilot Study.
Tatyana A Grushko, Virginia L Filiaci, Anthony G Montag, Marsha Apushkin, Maria J Gomez, Michael W Method

Appl Immunohistochem Mol Morphol· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Front-line chemo-immunotherapy with carboplatin-paclitaxel using oregovomab indirect immunization in advanced ovarian cancer: A randomized phase II study.
Molly Brewer, Roberto Angioli, Giovani Scambia, Domenica Lorusso, Corrado Terranova, Michael Method

Gynecol Oncol· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nomogram for Predicting Individual Survival After Recurrence of Advanced-Stage, High-Grade Ovarian Carcinoma.
Peter G Rose, James J Java, Ritu Salani, Melissa A Geller, Angeles Alvarez Secord, Michael W Method

Obstet Gynecol· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Creation and Implementation of an Environmental Scan to Assess Cancer Genetics Services at Three Oncology Care Settings.
Erica M Bednar, Michael T Walsh, Ellen Baker, Kimberly I Muse, Holly D Oakley, Michael W Method

J Genet Couns· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging (FIRES trial): a multicentre, prospective, cohort study.
Emma C Rossi, Lynn D Kowalski, Jennifer Scalici, Leigh Cantrell, Kevin Schuler, Michael Method

Lancet Oncol· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cognitive function during and six months following chemotherapy for front-line treatment of ovarian, primary peritoneal or fallopian tube cancer: An NRG oncology/gynecologic oncology group study.
Lisa M Hess, Helen Q Huang, Alexandra L Hanlon, William R Robinson, Rhonda Johnson, Michael Method

Gynecol Oncol· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Regulated delivery of molecular cargo to invasive tumour-derived microvesicles.
James W Clancy, Alanna Sedgwick, Carine Rosse, Vandhana Muralidharan-Chari, Graca Raposo, Michael Method

Nat Commun· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240).
Richard T Penson, Helen Q Huang, Lari B Wenzel, Bradley J Monk, Sharon Stockman, Michael Method

Lancet Oncol· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Catumaxomab for the treatment of malignant ascites in patients with chemotherapy-refractory ovarian cancer: a phase II study.
Jonathan S Berek, Robert P Edwards, Lynn P Parker, Leslie R DeMars, Thomas J Herzog, Michael W Method

Int J Gynecol Cancer· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis